Confo Therapeutics, a spin-off from VUB, has teamed up with Daiichi Sankyo to discover and develop small molecule drugs targeting G-protein coupled receptors (GPCRs) associated with central nervous system (CNS) diseases, which are conditions that affect the brain and spinal cord.
Confo Therapeutics will deploy its GPCR platform to identify lead compounds, while Daiichi Sankyo has the option to exclusively license and advance the resulting compounds. The collaboration includes upfront payments, development and commercial milestones, and royalties.
Cedric Ververken, CEO of Confo Therapeutics, highlights the potential to create new therapeutic options for patients by leveraging their expertise and innovative technologies to tackle a high unmet medical need.